Fludarabine

製品コードS1491 別名:FaraA, Fludarabinum

Fludarabine化学構造

分子量(MW):285.23

Fludarabine is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells.

サイズ 価格(税別)  
JPY 20932.00
JPY 16102.00
JPY 51460.00
JPY 78020.00

カスタマーフィードバック(4)

  • ERK signaling regulates STAT1 phosphorylation, and pSTAT1 modulates MHC II expression in the spinal cord under BCP conditions. AG490 (5 μg in 10 μL), Fludarabine (10 μg in 10 μL), or U0126 (5 μg in 10 μL) was intrathecally injected into cancer-bearing rats once a day for 14 days, beginning immediately after carcinoma cell inoculation (n = 3 in each group). (A) Representative western blot showing pSTAT1ser727, total STAT1, pERK42/44, total ERK42/44, CIITA, MHC II RTIB, and b actin protein levels in the spinal cords of BCP rats.

    Brain Behav Immun, 2017, 60:161-173. Fludarabine purchased from Selleck.

    Imatinib mesylate (IM) in combination of fludarabine phosphate (F-AMP) significantly inhibits Ki67 and c-KIT expression in GIST-T1 tumor xenografts. Tumors were collected on the day after the last treatment and were then subjected to immunohistochemical detection of Ki67 and c-KIT expression. Representative images of immunohistochemical staining of Ki67 and c-KIT in mice tumors.

    Mol Cancer Ther, 2014, 13(10): 2276-87 . Fludarabine purchased from Selleck.

  • Normal human KC pretreated with STAT1 inhibitor (fludarabine [10 uM]) or STAT3 inhibitor (STA-21 [2 uM]) for 24 h. The mRNA levels of hBD2 and hBD3 were assessed by qRT-PCR.

    Mol Cell Biol 2014 34(24), 4368-78.. Fludarabine purchased from Selleck.

    Bacterial infection in IPEC-J2 cells. The invasion and attachment of EHECO157:H7 was increased in the IPEC-J2 cells in the presence of 10 μM fludarabine. Data are expressed as the mean ± SEM (n= 6). Differences between groups were determined by paired samples t-test. *P<0.05 compared with the control.

    Int Immunopharmacol, 2016, 36:199-204.. Fludarabine purchased from Selleck.

製品安全説明書

STAT阻害剤の選択性比較

生物活性

製品説明 Fludarabine is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells.
ターゲット
STAT1 [4]
(Vascular smooth muscle cells)
体外試験

Fludarabine efficiently inhibits the proliferation of RPMI 8226 cells with IC50 of 1.54 μg/mL. The IC50 of Fludarabine against MM.1S and MM.1R cells is 13.48 μg/mL and 33.79 μg/mL, respectively. In contrast, U266 cells are resistant to Fludarabine with IC50 of 222.2 μg/mL. Fludarabine treatment results in increased number of cells in the G1 phase of cell cycle, accompanied with a concomitant reduction of cells at the S phase of cell cycle in a time-dependent manner. Fludarabine induces a cell cycle block and triggers apoptosis in MM cells. Fludarabine triggers time-dependent cleavage of caspase-8, -9, and -3, -7, followed by PARP cleavage. Fludarabine increases expression of Bax in a time-dependent fashion, while the expression of Bak doesn't change. After exposure to Fludarabine for 12 hours, RPMI 8226 cells shows a loss of membrane potential with 61.05% of the cells expressing low fluorescence of rhodamine 123 compared with 8.62% of cells in untreated control. [1] To enhance solubility, Fludarabine is formulated as the monophosphate (F-ara-AMP, fudarabine), which is instantaneously and quantitatively dephosphorylated to the parent nucleoside upon intravenous infusion. Inside the cells rephosphorylation occurs which leads to fuoroadenine arabinoside triphosphate (F-ara-ATP), the major cytotoxic metabolite of F-ara-A. [2] Fludarabine can also induce pro-inflammatory stimulation of monocytic cells, as evaluated by increased expression of ICAM-1 and IL-8 release. [3] Fludarabine does not affect the growth of ovarian cancer cell lines, whereas it induces marked and dose-dependent inhibition of proliferation in melanoma cell lines. [4] Fludarabine induces significant reduction of STAT-1 phosphorylation, whereas it does not change JAK2 activation. Interestingly, Fludarabine does not significantly affect the phosphorylation of these three STAT proteins. Fludarabine (1.5 mg) significantly prevents STAT-1 phosphorylation and also reduces the increased amount of this protein. No significant changes are demonstrated in JAK2 phosphorylation at 2 days, but Fludarabine inhibits JAK2-increased expression at 7 days. Fludarabine specifically inhibits STAT-1 activation without affecting other STAT proteins and consequently diminishes VSMC proliferation. [5]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Jeko-1  NH3MXnRHfW6ldHnvckBCe3OjeR?= M4nDXFIxKM7:TR?= Mn3BNlQhcA>? NVzVWZB7cW6qaXLpeJMh\XiycnXzd4lwdiCxZjDJSG8> MYWyOVk1ODdzMh?=
MV-4-11 MoTHRZBweHSxc3nzJGF{e2G7 NVjTfI9MOi53IN88US=> MoTyOFghcA>? MVrpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= Mm\4NlUyOTF3OEO=
THP-1 M2TFSWFxd3C2b4Ppd{BCe3OjeR?= M3iyR|IvPSEQvF2= MoDoOFghcA>? MnzYbY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= NWnKO4cyOjVzMUG1PFM>
MOLM 13 MXXBdI9xfG:|aYOgRZN{[Xl? NVz6XIc6Oi53IN88US=> NGXlTYM1QCCq NXrV[3VGcW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk> MYOyOVEyOTV6Mx?=
KBM3/Bu2506 Mln0RZBweHSxc3nzJGF{e2G7 NUjhPVBnOi53IN88US=> MX20PEBp M33i[4lv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 MmXCNlUyOTF3OEO=
Nalm-6 NUm2NFdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPLUXJKSzVyPUG4JO69VQ>? MYOyOVA3OTFyMR?=
Reh MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2S4VGlEPTB;M{Cg{txO NVPBV5FGOjVyNkGxNFE>
U2937 NUW3NXI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTF4IN88US=> NHfoPIszPTB4MUGwNS=>
Mec-1 NVLUOphKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfXTWM2OO,:nkWwNEDPxE1? NVfHdWtEOjVyNkGxNFE>
RPMI-8226 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHrTWM2OD13MECg{txO MVqyOVA3OTFyMR?=
Molt-4 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLMTWM2OD1zOECg{txO NUHI[|hVOjVyNkGxNFE>
Nalm-6-FluR NF;XSJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrwSmY1UUN3ME2yOVAh|ryP M2HHO|I2ODZzMUCx
Raji  NWLufmR6TnWwY4Tpc44hSXO|YYm= NXm2WnF6O8LizszN MWKyOE81QC95MjDo M2jM[olv\HWlZYOgZYNkfW23bHH0bY9veyCxZjDwOVMtKHB4MzDhcoQheDd|wrC= M3HPXlI1QTRyNkm1
PBMC M2Xs[GZ2dmO2aX;uJGF{e2G7 M1vBcFUxNzFyMDFOwG0> MV[yOEBp M1;rPGROW09? Ml;DbY5pcWKrdIOgV3RCXDFicHjvd5Bpd3K7bHH0bY9v MlrtNlQ6OTF6N{K=
MDA-231 MY\GeY5kfGmxbjDBd5NigQ>? M1yze|ExOCEQvF2= NEizWI4zPCCq MVnEUXNQ M2T5UYRm[3KnYYPld{BKTE9iZYjwdoV{e2mxbh?= NYPV[2dnOjR7MUG4O|I>
624.38mel  NFL5dFhHfW6ldHnvckBCe3OjeR?= M2nQcFUxKM7:TR?= NV;MSZYyOjRiaB?= MVLEUXNQ MXrk[YNz\WG|ZYOgTWRQKGW6cILld5Nqd25? NGiweGczPDlzMUi3Ni=>
MDA-231 M2flZ2Z2dmO2aX;uJGF{e2G7 Mni4OVAuOjByIN88US=> MnfpNlQhcA>? MmD5SG1UVw>? NUnhe|VlcW6qaXLpeJMhUUSRIHHjeIl3cXS7IHnu[IVx\W6mZX70cJkhd2ZibWLORUBt\X[nbIO= NVzqWZdbOjR7MUG4O|I>
624.38mel  M33tXmZ2dmO2aX;uJGF{e2G7 NHzDZY42OC1{MECg{txO NXH5b2FUOjRiaB?= NWrUd5U2TE2VTx?= MoPrbY5pcWKrdIOgTWRQKGGldHn2bZR6KGmwZHXw[Y5l\W62bImgc4YhdVKQQTDs[ZZmdHN? MnjLNlQ6OTF6N{K=
HMECs MV;GeY5kfGmxbjDBd5NigQ>? MV:xNFDDqM7:TdMg NF3QVI4{PsLiaB?= M2TYfYlvcGmkaYTzJGlHVs7|wrDhcoQhVFCVIHnu[JVk\WRiU2TBWFEheGixc4Doc5J6dGG2aX;uJIFv\CCLUl[xJIV5eHKnc4Ppc44> NWC2[ZpqOjR{MUGzNlc>
HMECs  Ml;YSpVv[3Srb36gRZN{[Xl? MXmxNFDDqM7:TdMg MWizOuKhcA>? NUXzU49FcW6qaXLpeJMhUU[QzsJCpI1m\GmjdHXkJJBpd3OyaH;yfYxifGmxbjDv[kBUXEGWMTDhcoQhW1SDVEOsJIJ2fCCwb4Sgc4YhW1SDVEK= Mm\kNlQzOTF|Mke=
BJAB M2DmfmFxd3C2b4Ppd{BCe3OjeR?= MWO1xsDPxE1? MlrONlQhcA>? NX\2fY1YcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M4LaWVI1ODV5MUS3
I-83 Mn71RZBweHSxc3nzJGF{e2G7 NYS3e4g1PcLizszN MmDhNlQhcA>? MkPXbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NVXUOWhqOjRyNUexOFc>
NALM6 MUTBdI9xfG:|aYOgRZN{[Xl? MVu1xsDPxE1? MkTLNlQhcA>? M3LsO4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M4L2eFI1ODV5MUS3
DU-145 MmfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYmwMVExKM7:Zz;tcC=> Mm\4OFghcMLi M4\nT4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MV6yN|c{PDhzNR?=
Nalm-6 MWLGeY5kfGmxbjDBd5NigQ>? M{naZ|ExyqEQvF2= NVfNVFF7OS9{L{SgbC=> NHnMNJFqdmS3Y3XzJIF2fG:yaHHnfS=> NFnYNmEzOzZ6MUKyNy=>
Reh MlHqSpVv[3Srb36gRZN{[Xl? Mnq4NVDDqM7:TR?= NWrIeVRmOS9{L{SgbC=> MWXpcoR2[2W|IHH1eI9xcGGpeR?= M1HJOFI{PjhzMkKz
Nalm-6 NVHsWHBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;lU5NXUUN3MDFijNwyOOLCid88US=> NWK3VJN3OjN4OEGyNlM>
Reh MnTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LsWWlEPTBi4pk8NVDjiIoQvF2= NIjhXIQzOzZ6MUKyNy=>
HEC1A MlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGX2PZMyODBvNUCwJO69VQ>? MVyyOEBp NFnJTWVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MWqyN|U6PTZ7Nx?=
AN3CA NEXhV|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTzWW4yODBvNUCwJO69VQ>? MYeyOEBp NYTPdG9wcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MYCyN|U6PTZ7Nx?=
HEC50B MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV2xNFAuPTByIN88US=> M1HxSVI1KGh? MkO3bY5pcWKrdIOgZ4VtdCCpcn;3eIghe2yrZ3j0cJk> NGD0TXMzOzV7NU[5Oy=>
HEC1A Moq5RZBweHSxc3nzJGF{e2G7 NHrWVnozOC9zMECg{txO NYPidINvOjRiaB?= MVXpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NWPrT2xyOjN3OUW2PVc>
AN3CA NH:2Wo5CeG:ydH;zbZMhSXO|YYm= NUHuNXQ1OjBxMUCwJO69VQ>? M4fDUVI1KGh? M2rWbolv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NVy5cYdoOjN3OUW2PVc>
HEC50B MXXBdI9xfG:|aYOgRZN{[Xl? M{HDelIxNzFyMDFOwG0> NV;EboJ7OjRiaB?= NFvGcmZqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=> Mn:wNlM2QTV4OUe=
EHEB MXfBdI9xfG:|aYOgRZN{[Xl? M{mxUVQxKM7:TR?= Mn3nNlQhcA>? NXzJSWlIcW6mdXPld{BieG:ydH;zbZM> M1;ENFI{PDl5MEe1
A549 NInRW3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4m5PWlEPTB;MUWuO:KyOi56INM1US=> M2fyU|I{Ozd5MUmy
A549 GAPDH-deficient MmnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPaXGVKSzVyPUG4MlXDuTJwMzFCuW0> MmjENlM{PzdzOUK=
CLL  NITSbYhCeG:ydH;zbZMhSXO|YYm= M33TSVExKM7:TdMg M4XZWVI1NTl4IHi= MWPpcoR2[2W|IHHwc5B1d3SrYzDj[YxtKGSnYYTo NVv0WFJPOjJ{MEe2PFY>
MEC1 MV;BdI9xfG:|aYOgRZN{[Xl? NWfJXmwyOTBywrFOwG0> M321TlczKGh? NYjkdVBncW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?= M3OzZ|IzOTN{OUez
U937  Mn\DRZBweHSxc3nzJGF{e2G7 MYmwMlgh|ryP M2LTelQuPDhiaB?= NWLsVZV{cW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk> M{j4VVIzODd2N{Cw
U937  MnK0RZBweHSxc3nzJGF{e2G7 NEniXnYyKM7:TR?= MmrpPVYhcA>? MnL3bY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= MkS2NlIxOjN3MkO=
Daudi MmPMRZBweHSxc3nzJGF{e2G7 Ml3UNlAh|ryP M4\YTVk3KGh? NYf1dpU3cW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk> NVrRWI9wOjJyMkO1NlM>
J45.01 NHy1R|dCeG:ydH;zbZMhSXO|YYm= NFr0PGYyKM7:TR?= M324XFk3KGh? MV7pcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= M4PBWVIzODJ|NUKz
RPMI 8226 MormS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPHRWxKSzVyPUK1MlnDqMLzwrCzMlch|ryP NHLzUmczOTl2OEK2OC=>
CEM MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXjTWM2OD1{LkVCpOKyyqByLkSg{txO NGLEfngzOTl2OEK2OC=>
Raji M4\G[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFi2bHNKSzVyPUCuOFfDqMLzwrCwMlA1KM7:TR?= M37nfVIyQTR6Mk[0
U937 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\URVJKSzVyPUCuNlTDqMLzwrCwMlA1KM7:TR?= NVP3NVNPOjF7NEiyOlQ>
K562 M2PEXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXnW|hMUUN3ME2wMlQ1yqEEsdMgNE4xPSEQvF2= M{mxUlIyQTR6Mk[0
NALM-6 MmjxRZBweHSxc3nzJGF{e2G7 NIDXUGkyOCEQvF5CpC=> M2DBelI1KGh? Ml;SbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|bHnnbJRtgQ>? NInjNIIzOTZ7OUO4Ny=>
JMV-3 MlSxRZBweHSxc3nzJGF{e2G7 NWn3R21SOTBizszNxsA> NHz1c5kzPCCq NH6xPJBqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPsbYdpfGy7 M1;qSlIyPjl7M{iz
EHEB MnjySpVv[3Srb36gRZN{[Xl? MkTyOU02OCEQvF2= NHizfIIzPCCq MlfG[IVkemWjc3XzJJAzOSCneIDy[ZN{cW:wIIPp[45q\mmlYX70cJk> M3;adFIyOTZ6M{mx
JVM-2  MULGeY5kfGmxbjDBd5NigQ>? MoHiN|Ah|ryP MWGyOEBp NVz6[ZNM\GWlcnXhd4V{KHB{MTDlfJBz\XO|aX;u MonHNlEyPjh|OUG=
KBM3/Bu2506 Mn\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrUTWMzOD1yLk[3JOK2VQ>? NGrpN4EzODl|M{WwPS=>
KBM3/Bu2506 M2HReWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfSNE43KM7:TR?= Mnv0NlQhcA>? NHnTRZhqdmO{ZXHz[ZMhfGinIHPlcIwh\nKjY4Tpc44hcW5iUz3wbIF{\Q>? MYKyNFk{OzVyOR?=
MDA-MB-231 M3z0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLmUI1EUUN3ME20MlAh|ryP NInOeJczODR2N{O5NC=>
MCF-7 M3L0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTF3LkCg{txO MV:yNFQ1PzN7MB?=
HLE-B3  M3vuSWZ2dmO2aX;uJGF{e2G7 NFHkTHozPSEQvF2= MlLXOFghcA>? MV3icI9kc3NiSV\OMe6{6oDVaX7keYNm\CCVVFHUNUBxcG:|cHjvdplt[XSrb36gZY5lKEmGTzDlfJBz\XO|aX;u NGDhXGEzODR|NUG1PC=>
K562 M4LSTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXe3NkBp NF7hNXpKSzVyPUOuN{BvVQ>? MV6yNFMxPzF7OB?=
BW-225 M4jMcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXv3NlRPUUN{ME2xMlM4KMPZMUFijLI5yqEQvF5CpC=> NX3rV2VqOTh4NkGzPFA>
OH-65 NE[3UYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\ETWMzOD1zLkO3JOOYOTEkiKK4xsDPxE4EoB?= NGO3VnoyQDZ4MUO4NC=>
GR-145 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|IxRTJwN{Sgx7chOTEkiKK4JEDPxE4EoB?= M{DYelE5PjZzM{iw
A549 Mo\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfQdGhKSzJyPUWuOFghy5diMUFijLI5KM7:TdMg NIDsW5oyQDZ4MUO4NC=>
CaSki  NXO0WHNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|IxRTFwM{egx7chOTEkiKK3JO69VcLi NHu3TooyQDZ4MUO4NC=>
ZMK-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XkWGlEOjB;MT6zO{DEnyBzMPMIllYh|ryPwrC= MYGxPFY3OTN6MB?=
SKW6.4 MYXBdI9xfG:|aYOgRZN{[Xl? M{O4NVAvODFvMUCg{txO M3fSdVI1NzR6IHi= M4nyXolv\HWlZYOgZ4VtdCCmZXH0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLTDk[ZBmdmSnboSgcYFvdmW{ NVrZNWtIOThyOUKzOFA>
RPMI 8226 NVvyZ3VMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2WwOVI1KGh? M4H3SmlEPTB;MT61OOKh|ryP NVPzWI1GOTd7N{[xPFY>
MM.1S NV7oeVJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFuxRXE1QCCq MljRTWM2OD1zMz60POKh|ryP NXP2ZY1lOTd7N{[xPFY>
MM.1R NGXnPZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoG4OFghcA>? MkC5TWM2OD1|Mz63PUDPxE1? MXqxO|k4PjF6Nh?=
U937 NITwOIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfXO5hQUUN3ME2zMFIxOCEEsTC1OlAhdk1? M{DIflE2QTNyM{[x

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Tumors treated with PBS grow rapidly to approx-imately 10-fold their initial volume in 25 day, whereas, the tumors in the Fludarabine at 40 mg/kg increase less than 5-fold. A significant antitumor effect of 40 mg/kg Fludarabine on RPMI8226 tumor growth is demonstrated. RPMI8226 tumors treated with 40 mg/kg Fludarabine at day 10 increase apoptotic nuclei. Fludarabine is effective in suppressing RPMI8226 myeloma xenografts in SCID mice. [1]

お薦めの試験操作(参考用のみ)

細胞試験:

[1]

+ 展開
  • 細胞株: Dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines
  • 濃度: 2 μg/mL
  • 反応時間: 24 hours
  • 実験の流れ:

    After treated with Fludarabine or control, dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines (5 × 105 cells) are washed twice in phosphate-buffered saline (PBS) and fixed with 70% ice-cold ethanol, then centrifuged and suspended in PBS containing 100 μg/mL RNase A. After incubated for 30 minutes at 37 ºC, samples are resuspended in 25 μg/mL propidium iodide. Flow cytometry is performed on a FACSCalibur automated system. Apoptosis is determined by Annexin V-FITC apoptosis detection kit, according to the manufacturer's instructions. For TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling) assay, cells are analyzed by flow cytometry using the in situ cell death detection kit.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Severe combined immunodeficient (SCID) mice bearing RPMI 8226 cells
  • 製剤: PBS
  • 投薬量: 40 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 57 mg/mL (199.83 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
30% propylene glycol, 5% Tween 80, 65% D5W
混合させたのち直ちに使用することを推奨します。
30 mg/mL (suspension)

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 285.23
化学式

C10H12FN5O4

CAS No. 21679-14-1
保管
in solvent
別名 FaraA, Fludarabinum

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01585415 Terminated Metastatic Cancer|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 9, 2012 Phase 1
NCT01503242 Recruiting Plasma Cell Myeloma|Refractory Plasma Cell Myeloma Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) January 9, 2012 Phase 1
NCT01319565 Active, not recruiting Metastatic Melanoma|Skin Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) March 9, 2011 Phase 2
NCT01145209 Active, not recruiting Small Lymphocytic Lymphoma|CLL (Chronic Lymphocytic Leukemia) National Heart, Lung, and Blood Institute (NHLBI)|University of Virginia|GlasoSmithKline|National Institutes of Health Clinical Center (CC) June 9, 2010 Phase 2
NCT02500576 Recruiting Melanoma M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.|Prometheus Inc. August 7, 2015 Phase 2
NCT01174121 Recruiting Metastatic Colorectal Cancer|Metastatic Gastric Cancer|Metastatic Pancreatic Cancer|Metastatic Hepatocellular Carcinoma|Metastatic Cholangiocarcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2010 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    how to re-suspend and deliver the inhibitor for in vivo experiments?

  • 回答:

    For S1491, Fludarabine, we tested a vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W that you can resuspend the compound in at up to 30mg/ml. It's a suspension and can only be given via oral gavage.

STATシグナル伝達経路

相関STAT製品

Tags: Fludarabineを買う | Fludarabine ic50 | Fludarabine供給者 | Fludarabineを購入する | Fludarabine費用 | Fludarabine生産者 | オーダーFludarabine | Fludarabine化学構造 | Fludarabine分子量 | Fludarabine代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID